 Halis Akturk
Concepts (214)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 57 | 2024 | 3254 | 10.110 |
Why?
| | Blood Glucose Self-Monitoring | 35 | 2024 | 500 | 7.110 |
Why?
| | Blood Glucose | 41 | 2024 | 1824 | 5.080 |
Why?
| | Hypoglycemic Agents | 27 | 2024 | 1008 | 4.640 |
Why?
| | Hypoglycemia | 9 | 2024 | 386 | 3.750 |
Why?
| | Insulin | 27 | 2024 | 2082 | 2.690 |
Why?
| | Insulin Infusion Systems | 16 | 2024 | 296 | 2.650 |
Why?
| | Diabetic Ketoacidosis | 7 | 2022 | 159 | 2.470 |
Why?
| | Antineoplastic Agents, Immunological | 4 | 2022 | 154 | 2.110 |
Why?
| | Programmed Cell Death 1 Receptor | 4 | 2019 | 193 | 1.820 |
Why?
| | Diabetes Mellitus, Type 2 | 11 | 2023 | 2098 | 1.660 |
Why?
| | Ketosis | 2 | 2022 | 12 | 1.580 |
Why?
| | Insulins | 3 | 2023 | 32 | 1.580 |
Why?
| | Hyperglycemia | 3 | 2021 | 294 | 1.570 |
Why?
| | Diabetes Mellitus | 7 | 2024 | 906 | 1.480 |
Why?
| | Device Removal | 2 | 2021 | 128 | 1.340 |
Why?
| | Antibodies, Monoclonal | 3 | 2020 | 1265 | 1.290 |
Why?
| | Humans | 80 | 2024 | 115586 | 1.140 |
Why?
| | Thyrotoxicosis | 1 | 2024 | 8 | 0.980 |
Why?
| | Pancreas, Artificial | 2 | 2023 | 68 | 0.970 |
Why?
| | Cannabis | 3 | 2022 | 381 | 0.950 |
Why?
| | Melanoma | 2 | 2022 | 651 | 0.940 |
Why?
| | Testosterone | 2 | 2017 | 337 | 0.900 |
Why?
| | Sweetening Agents | 1 | 2023 | 37 | 0.870 |
Why?
| | Adult | 31 | 2024 | 30718 | 0.840 |
Why?
| | Cell Cycle Checkpoints | 2 | 2020 | 84 | 0.830 |
Why?
| | Weight Loss | 3 | 2024 | 633 | 0.820 |
Why?
| | HLA-DR Antigens | 1 | 2022 | 221 | 0.790 |
Why?
| | Insulin, Long-Acting | 3 | 2021 | 52 | 0.740 |
Why?
| | Blindness | 1 | 2020 | 37 | 0.710 |
Why?
| | B7-H1 Antigen | 2 | 2019 | 139 | 0.700 |
Why?
| | Postprandial Period | 2 | 2024 | 88 | 0.660 |
Why?
| | Prostheses and Implants | 1 | 2020 | 140 | 0.640 |
Why?
| | Pregnancy in Diabetics | 1 | 2019 | 82 | 0.640 |
Why?
| | Biosensing Techniques | 1 | 2020 | 102 | 0.640 |
Why?
| | Thyroid Hormones | 1 | 2018 | 53 | 0.600 |
Why?
| | Sulfonylurea Compounds | 1 | 2018 | 44 | 0.600 |
Why?
| | Nonprescription Drugs | 1 | 2018 | 68 | 0.580 |
Why?
| | Thyroidectomy | 1 | 2017 | 52 | 0.580 |
Why?
| | Registries | 2 | 2024 | 1770 | 0.580 |
Why?
| | Hypoparathyroidism | 1 | 2017 | 4 | 0.570 |
Why?
| | Osteomalacia | 1 | 2017 | 4 | 0.570 |
Why?
| | Wolfram Syndrome | 1 | 2017 | 4 | 0.570 |
Why?
| | Eunuchism | 1 | 2016 | 3 | 0.570 |
Why?
| | Immunologic Factors | 1 | 2019 | 220 | 0.570 |
Why?
| | Hypogonadism | 1 | 2017 | 74 | 0.550 |
Why?
| | Quality of Life | 3 | 2023 | 2385 | 0.540 |
Why?
| | Telemedicine | 1 | 2024 | 667 | 0.540 |
Why?
| | Hormone Replacement Therapy | 1 | 2016 | 77 | 0.530 |
Why?
| | Male | 27 | 2024 | 55949 | 0.530 |
Why?
| | Graft Rejection | 1 | 2018 | 533 | 0.500 |
Why?
| | Protein Kinase Inhibitors | 1 | 2020 | 790 | 0.480 |
Why?
| | Adrenal Cortex Hormones | 1 | 2018 | 509 | 0.470 |
Why?
| | Elephantiasis | 1 | 2014 | 3 | 0.470 |
Why?
| | Middle Aged | 16 | 2024 | 26999 | 0.470 |
Why?
| | Dietary Supplements | 1 | 2018 | 458 | 0.470 |
Why?
| | Thyroid Neoplasms | 1 | 2017 | 262 | 0.460 |
Why?
| | Female | 24 | 2024 | 59913 | 0.450 |
Why?
| | Cryptogenic Organizing Pneumonia | 1 | 2013 | 17 | 0.440 |
Why?
| | Antibodies, Antineutrophil Cytoplasmic | 1 | 2013 | 33 | 0.430 |
Why?
| | Alcohol Drinking | 1 | 2017 | 648 | 0.400 |
Why?
| | Young Adult | 9 | 2023 | 10470 | 0.330 |
Why?
| | Cardiovascular Diseases | 2 | 2017 | 1724 | 0.330 |
Why?
| | Neoplasms | 2 | 2020 | 2118 | 0.320 |
Why?
| | Self-Injurious Behavior | 2 | 2020 | 114 | 0.310 |
Why?
| | Treatment Outcome | 7 | 2024 | 9159 | 0.300 |
Why?
| | Technology | 3 | 2023 | 79 | 0.290 |
Why?
| | Adolescent | 8 | 2024 | 17889 | 0.260 |
Why?
| | Immunotherapy | 2 | 2020 | 479 | 0.260 |
Why?
| | Weight Gain | 2 | 2018 | 453 | 0.250 |
Why?
| | Norway | 1 | 2024 | 36 | 0.240 |
Why?
| | Child | 6 | 2024 | 18488 | 0.230 |
Why?
| | Suicide | 2 | 2020 | 501 | 0.230 |
Why?
| | Sensitivity and Specificity | 2 | 2022 | 1718 | 0.220 |
Why?
| | Retrospective Studies | 6 | 2024 | 12608 | 0.220 |
Why?
| | Diagnosis, Differential | 3 | 2017 | 1357 | 0.210 |
Why?
| | Receptors, Glucagon | 1 | 2022 | 23 | 0.210 |
Why?
| | Goals | 1 | 2024 | 158 | 0.210 |
Why?
| | Mobile Applications | 1 | 2024 | 140 | 0.210 |
Why?
| | Diabetic Retinopathy | 1 | 2024 | 149 | 0.200 |
Why?
| | Ketone Bodies | 1 | 2021 | 13 | 0.200 |
Why?
| | 3-Hydroxybutyric Acid | 1 | 2021 | 14 | 0.200 |
Why?
| | Gastric Emptying | 1 | 2021 | 40 | 0.190 |
Why?
| | Administration, Inhalation | 2 | 2024 | 644 | 0.190 |
Why?
| | Reference Standards | 1 | 2021 | 161 | 0.190 |
Why?
| | Breath Tests | 1 | 2021 | 83 | 0.190 |
Why?
| | Ketones | 1 | 2021 | 44 | 0.190 |
Why?
| | Infrared Rays | 1 | 2021 | 21 | 0.190 |
Why?
| | Feasibility Studies | 1 | 2024 | 741 | 0.190 |
Why?
| | Risk Factors | 6 | 2019 | 8697 | 0.180 |
Why?
| | Energy Intake | 1 | 2023 | 414 | 0.180 |
Why?
| | Health Behavior | 2 | 2023 | 707 | 0.180 |
Why?
| | Overweight | 1 | 2024 | 469 | 0.180 |
Why?
| | Alleles | 1 | 2022 | 794 | 0.170 |
Why?
| | Gastroparesis | 1 | 2019 | 8 | 0.170 |
Why?
| | Prevalence | 3 | 2023 | 2264 | 0.160 |
Why?
| | Insulin Aspart | 1 | 2018 | 26 | 0.160 |
Why?
| | Glucosides | 1 | 2018 | 36 | 0.160 |
Why?
| | Glycosides | 1 | 2018 | 33 | 0.150 |
Why?
| | Health Services Accessibility | 1 | 2024 | 771 | 0.150 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2022 | 667 | 0.150 |
Why?
| | Benzhydryl Compounds | 1 | 2018 | 60 | 0.150 |
Why?
| | Injections | 1 | 2018 | 161 | 0.150 |
Why?
| | Cost of Illness | 1 | 2019 | 257 | 0.150 |
Why?
| | Software | 1 | 2021 | 541 | 0.150 |
Why?
| | United States Food and Drug Administration | 1 | 2018 | 173 | 0.150 |
Why?
| | Antidiuretic Agents | 1 | 2017 | 7 | 0.140 |
Why?
| | Marijuana Abuse | 1 | 2019 | 209 | 0.140 |
Why?
| | Ergolines | 1 | 2016 | 3 | 0.140 |
Why?
| | Self Care | 1 | 2019 | 354 | 0.140 |
Why?
| | Dopamine Agonists | 1 | 2016 | 31 | 0.140 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2017 | 70 | 0.140 |
Why?
| | Patient Admission | 1 | 2018 | 175 | 0.140 |
Why?
| | Osteosarcoma | 1 | 2017 | 66 | 0.140 |
Why?
| | Health Personnel | 1 | 2022 | 581 | 0.140 |
Why?
| | Hydrocortisone | 1 | 2018 | 273 | 0.140 |
Why?
| | Prolactin | 1 | 2016 | 95 | 0.140 |
Why?
| | Prospective Studies | 3 | 2024 | 6264 | 0.140 |
Why?
| | Cross-Sectional Studies | 2 | 2023 | 4435 | 0.130 |
Why?
| | Marijuana Smoking | 1 | 2019 | 224 | 0.130 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1216 | 0.130 |
Why?
| | Drug Delivery Systems | 1 | 2018 | 301 | 0.130 |
Why?
| | Case-Control Studies | 1 | 2022 | 3022 | 0.130 |
Why?
| | Pituitary Neoplasms | 1 | 2016 | 157 | 0.130 |
Why?
| | Bone Neoplasms | 1 | 2017 | 194 | 0.120 |
Why?
| | Body Mass Index | 2 | 2024 | 1971 | 0.120 |
Why?
| | Peptostreptococcus | 1 | 2014 | 2 | 0.120 |
Why?
| | United States | 3 | 2023 | 12295 | 0.120 |
Why?
| | Prognosis | 2 | 2020 | 3339 | 0.120 |
Why?
| | Lymphedema | 1 | 2014 | 20 | 0.120 |
Why?
| | Endocarditis, Bacterial | 1 | 2014 | 36 | 0.120 |
Why?
| | Mitral Valve Insufficiency | 1 | 2014 | 63 | 0.110 |
Why?
| | Pilot Projects | 1 | 2018 | 1377 | 0.110 |
Why?
| | Age Factors | 2 | 2019 | 2907 | 0.110 |
Why?
| | Heart Diseases | 1 | 2017 | 330 | 0.110 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2014 | 61 | 0.110 |
Why?
| | Time Factors | 1 | 2024 | 6165 | 0.110 |
Why?
| | Sex Characteristics | 1 | 2017 | 641 | 0.110 |
Why?
| | Incidence | 1 | 2019 | 2335 | 0.110 |
Why?
| | TRPC Cation Channels | 1 | 2012 | 11 | 0.110 |
Why?
| | Autoimmunity | 1 | 2018 | 822 | 0.110 |
Why?
| | Hemodynamics | 1 | 2017 | 968 | 0.110 |
Why?
| | Lymphokines | 1 | 2012 | 115 | 0.100 |
Why?
| | Platelet-Derived Growth Factor | 1 | 2012 | 82 | 0.100 |
Why?
| | Kidney Transplantation | 1 | 2018 | 558 | 0.100 |
Why?
| | Cough | 1 | 2013 | 107 | 0.100 |
Why?
| | Risk Assessment | 2 | 2019 | 2987 | 0.100 |
Why?
| | Radiography, Thoracic | 1 | 2013 | 165 | 0.100 |
Why?
| | Neuroprotective Agents | 1 | 2012 | 105 | 0.100 |
Why?
| | Pregnancy | 2 | 2022 | 5548 | 0.100 |
Why?
| | Obesity | 1 | 2024 | 2517 | 0.100 |
Why?
| | Skin Neoplasms | 1 | 2018 | 761 | 0.100 |
Why?
| | Reproducibility of Results | 3 | 2024 | 2800 | 0.090 |
Why?
| | Biomarkers, Tumor | 1 | 2017 | 1048 | 0.090 |
Why?
| | Acute Coronary Syndrome | 1 | 2014 | 254 | 0.090 |
Why?
| | Blood Pressure | 1 | 2016 | 1537 | 0.090 |
Why?
| | Hospitalization | 1 | 2018 | 1765 | 0.080 |
Why?
| | Biopsy | 1 | 2013 | 1056 | 0.080 |
Why?
| | Colorado | 1 | 2019 | 4113 | 0.080 |
Why?
| | Hypertension | 1 | 2016 | 1064 | 0.080 |
Why?
| | Chronic Disease | 1 | 2014 | 1598 | 0.080 |
Why?
| | Postoperative Complications | 1 | 2018 | 2161 | 0.070 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 4665 | 0.070 |
Why?
| | Hypoxia | 1 | 2013 | 937 | 0.070 |
Why?
| | Insulin, Short-Acting | 1 | 2024 | 4 | 0.060 |
Why?
| | Glucagon-Like Peptide-2 Receptor | 1 | 2024 | 3 | 0.060 |
Why?
| | Gastric Inhibitory Polypeptide | 1 | 2024 | 14 | 0.060 |
Why?
| | Apoptosis | 1 | 2012 | 2377 | 0.060 |
Why?
| | Transaminases | 1 | 2022 | 25 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2023 | 249 | 0.050 |
Why?
| | Artificial Intelligence | 1 | 2024 | 148 | 0.050 |
Why?
| | Glucagon | 1 | 2022 | 93 | 0.050 |
Why?
| | Lipoproteins, LDL | 1 | 2022 | 129 | 0.050 |
Why?
| | Needles | 1 | 2022 | 52 | 0.050 |
Why?
| | Benchmarking | 1 | 2022 | 163 | 0.050 |
Why?
| | Animals | 3 | 2018 | 32102 | 0.050 |
Why?
| | Fear | 1 | 2023 | 297 | 0.050 |
Why?
| | Double-Blind Method | 1 | 2022 | 1660 | 0.040 |
Why?
| | Skin | 1 | 2022 | 662 | 0.040 |
Why?
| | Electronic Health Records | 1 | 2024 | 805 | 0.040 |
Why?
| | Longitudinal Studies | 1 | 2024 | 2416 | 0.040 |
Why?
| | Glucose | 1 | 2022 | 904 | 0.040 |
Why?
| | Algorithms | 1 | 2024 | 1490 | 0.030 |
Why?
| | Quality Improvement | 1 | 2023 | 958 | 0.030 |
Why?
| | Adaptation, Psychological | 1 | 2019 | 551 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2018 | 645 | 0.030 |
Why?
| | Global Health | 1 | 2017 | 290 | 0.030 |
Why?
| | Ceftriaxone | 1 | 2014 | 18 | 0.030 |
Why?
| | Echocardiography, Transesophageal | 1 | 2014 | 89 | 0.030 |
Why?
| | Vancomycin | 1 | 2014 | 76 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2022 | 4440 | 0.030 |
Why?
| | ATPases Associated with Diverse Cellular Activities | 1 | 2012 | 5 | 0.030 |
Why?
| | Receptor, IGF Type 1 | 1 | 2013 | 58 | 0.030 |
Why?
| | Phosphatidylinositol 3-Kinase | 1 | 2012 | 26 | 0.030 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2012 | 60 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 1 | 2022 | 2392 | 0.030 |
Why?
| | Insulin Glargine | 1 | 2013 | 73 | 0.030 |
Why?
| | Glycogen Synthase Kinase 3 | 1 | 2012 | 77 | 0.030 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2012 | 136 | 0.030 |
Why?
| | Neuroblastoma | 1 | 2012 | 130 | 0.020 |
Why?
| | Microtubule-Associated Proteins | 1 | 2012 | 174 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2014 | 962 | 0.020 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2019 | 1198 | 0.020 |
Why?
| | Aged | 2 | 2021 | 19251 | 0.020 |
Why?
| | Dementia | 1 | 2012 | 185 | 0.020 |
Why?
| | Phosphorylation | 1 | 2012 | 1571 | 0.020 |
Why?
| | Myocardial Infarction | 1 | 2014 | 931 | 0.020 |
Why?
| | Calcium | 1 | 2012 | 1103 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2012 | 2751 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2014 | 1484 | 0.020 |
Why?
| | Neurons | 1 | 2012 | 1298 | 0.020 |
Why?
| | Rats | 1 | 2012 | 5034 | 0.010 |
Why?
| | Signal Transduction | 1 | 2012 | 4541 | 0.010 |
Why?
| | HIV Infections | 1 | 2012 | 2473 | 0.010 |
Why?
|
|
Akturk's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|